Stocks · News reference

NanoViricides shares are trading lower after the company announced the pricing of its approximately $3.8 million offering of 2,516,339 shares.

Jul 24, 2026, 12:34 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 18, 2026, 12:37 PMBenzinga Newsdesk
NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congo
Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies, has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the
Read original at benzinga
NNVC
BenzingaAug 10, 2026, 12:34 PMBenzinga Newsdesk
NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II Clinical
Read original at benzinga
NNVC
BenzingaJul 28, 2026, 12:35 PMBenzinga Newsdesk
NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a Phase II
Read original at benzinga
NNVC